News
Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback